BJH - volume 10, issue 3, may 2019
D. Bron MD, PhD, S. Wittnebel MD, PhD, V. Thibaud MD
After a successful first edition in Lisbon, a second edition of this scientific working group meeting was held in Warsaw in October 2018. The objective was to organise roundtables with scientists, clinicians, onconurses and patient’s organisations to improve the management of older patients with haematological disorders. Several unsolved issues were debated as outlined below.
(BELG J HEMATOL 2019;10(3):127–9)
Read moreBJH - volume 10, issue 1, february 2019
G. Verhoef MD, PhD
Hundreds of oral- and poster presentations were communicated during the 60th Annual Meeting of ASH in San Diego. Of course, it is impossible to cover all topics and give detailed highlights. In this presentation, I will give you my ‘favorites’, sometimes in a historical perspective. For a more complete overview of congress highlights, I refer to the other articles in this special issue of the BJH.
(BELG J HEMATOL 2019;10(1):3–10)
Read moreBJH - volume 10, issue 1, february 2019
T. Feys MBA, MSc
The introduction of targeted agents revolutionized the care for patients with chronic lymphocytic leukemia (CLL). While these agents first proved their clinical benefit in the treatment of patients with relapsed/refractory (R/R) disease and in CLL patients with dismal prognostic features (e.g. del(17p), TP53 mutations) they were subsequently also tested in the first-line setting and in patients without high-risk cytogenetic characteristics. During the 2018 annual meeting of the American Society of Hematology (ASH), results were presented of several pivotal trials that will likely change the frontline treatment paradigm for CLL patients. A second hot topic in CLL that received lots of attention at ASH 2018 consists of minimal residual disease (MRD). Several studies were presented looking into the feasibility of obtaining a MRD negative status with (combinations of) novel targeted agents in CLL and look into the prognostic significance of obtaining MRD negativity. Finally, R/R disease continues to be the setting in which novel therapeutic options are being tested. During ASH 2018 results of several clinical trials evaluating combinations of existing targeted agents were presented in addition to data on completely new therapeutics (e.g. chimeric antigen receptor [CAR] T cell therapy) that try to make their mark in CLL. This article will summarize some of the key highlights in CLL presented at ASH 2018.
(BELG J HEMATOL 2019;10(1):11–7)
Read moreBJH - volume 10, issue 1, february 2019
K. Fostier MD
Of the 4,872 abstracts presented during the 2018 annual meeting of the American Society of Hematology (ASH), almost a quarter was dedicated to MM, illustrating continued interest and research in this dismal disease. This text is but a small anthology on the most exciting abstracts on MM as presented at ASH 2018.
(BELG J HEMATOL 2019;10(1):20–3)
Read moreBJH - volume 10, issue 1, february 2019
M-C. Vekemans MD
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias resulting from ineffective hematopoiesis. MDS is associated with a risk for progression to acute myeloid leukemia (AML). Progress in the field of this disease aims at decreasing the transfusion burden, delaying progression to AML, improving the quality-of-life (QoL) of patients and extending the survival. Here, we report some recent advances presented at the 60th Annual Meeting of the American Society of Hematology (ASH).
(BELG J HEMATOL 2019;10(1):24–30)
Read moreBJH - volume 10, issue 1, february 2019
T. Feys MBA, MSc
With respect to chronic myeloid leukemia (CML), the 2018 annual meeting of the American Society of Hematology featured the following sessions: The CML educational session, 3 oral sessions with 6 abstract presentations each, and a long list of posters. This report will briefly summarize the key messages from the educational session discussing the choice of first-line treatment in CML patients. The highlights from the oral and poster sessions will be grouped in three categories: new drugs in CML, treatment-free remission (TFR) and CML and pregnancy.
(BELG J HEMATOL 2019;10(1):31–5)
Read moreBJH - volume 10, issue 1, february 2019
D. Selleslag MD
The ASH 2018 conference in San Diego featured a number of exciting new studies with clinical relevance for the treatment of patients with acute myeloid leukemia (AML). The key studies that are discussed here are grouped in 3 broad treatment groups: targeted therapies, immunotherapy and allogeneic stem cell transplantation (allo SCT).
(BELG J HEMATOL 2019;10(1):36–40)
Read more
Top
